ARTICLE | Management Tracks
Amgen veteran Lenz named head of R&D at Neumora
Plus: Eaton leaving Editas as CTO, CBO and updates from Poseida, Zevra, Pheon, Lexicon and more
October 10, 2023 11:14 PM UTC
Neumora Therapeutics Inc. (NASDAQ:NMRA) hired Robert Lenz as EVP, head of R&D. Lenz joins the brain disease company after an 11-year career with Amgen Inc. (NASDAQ:AMGN), where he was most recently SVP, head of global development. Neumora raised $250 million in an IPO on NASDAQ last month.
Editas Medicine Inc. (NASDAQ:EDIT) disclosed in an SEC filing the departure of EVP, CTO and CBO Bruce Eaton, effective Jan. 2, 2024. Eaton joined the gene editing company as SVP of chemistry and Boulder site head in January 2018. ...